Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | PDE5A | O76074 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15578291 | 0.83 | FFAR1 (0.43) | KCNH2RAB9ANPC1SMN1; SMN2FFAR1 | |
| SCHEMBL20746692 | 0.79 | KCNH2 (0.61) | KCNH2CYSLTR2CYSLTR1MAPTRAB9A | |
| SCHEMBL30212183 | 0.78 | SMN1; SMN2 (0.41) | KCNH2CYSLTR2CYSLTR1MRGPRX4RAB9A | |
| SCHEMBL27234037 | 0.78 | SMN1; SMN2 (0.41) | KCNH2CYSLTR2CYSLTR1MRGPRX4RAB9A | |
| SCHEMBL4569966 | 0.76 | KCNH2 (0.75) | KCNH2CYSLTR2CYSLTR1MAPTMRGPRX4 | |
| SCHEMBL29167411 | 0.76 | KCNH2 (0.34) | KCNH2CYSLTR2CYSLTR1 | |
| SCHEMBL24982790 | 0.76 | S1PR4 (0.43) | MAPTSMN1; SMN2TDP1 | |
| SCHEMBL17979331 | 0.75 | KCNA3 (0.47) | MAPTRAB9ANPC1KCNA3TSHR | |
| SCHEMBL12042913 | 0.75 | KCNH2 (0.56) | KCNH2CYSLTR2CYSLTR1MAPTRAB9A | |
| SCHEMBL17898221 | 0.75 | KCNH2 (0.56) | KCNH2CYSLTR2CYSLTR1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2020-02-18 | — | — | US | disclosed |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2019-02-19 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | ICOS, NFATC1, CD74 | KCNH2 3811/4885CYSLTR2 40/4885CYSLTR1 45/4885 |
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | KCNH2 3811/4885CYSLTR2 40/4885CYSLTR1 45/4885 |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | KCNH2 3811/4885CYSLTR2 40/4885CYSLTR1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.